Showing 6251-6260 of 10817 results for "".
- Platform Prints First Collagen-Based Bioink for Personalized Tissue Creationhttps://practicaldermatology.com/news/platform-prints-first-collagen-based-bioink-for-personalized-tissue-creation/2484559/Conexeu Sciences Inc. has announced the first 3D-printed tissue scaffolds created entirely from its proprietary extracellular matrix (ECM), according to a release from the manufacturer. Conexeu said their CXU™ platform, a bovin
- Study: Itch and Rash Severity Linked to Biologic Use in Eczemahttps://practicaldermatology.com/news/itch-and-rash-severity-linked-to-biologic-use-in-eczema-paper/2484499/Data from a recent pre-proof in the Journal of the American Academy of Dermatology highlights that both itch and lesion severity independently predict biologic treatment initiation in patients with moderate-to-severe atopic de
- Tralokinumab Maintains Efficacy in Hand AD Through 32 Weekshttps://practicaldermatology.com/news/tralokinumab-maintains-efficacy-in-hand-ad-through-32-weeks/2484484/LEO Pharma has announced positive 32-week topline results from its ADHAND trial, a phase 3b study evaluating tralokinumab in adults with moderate-to-severe atopic dermatitis (AD) with hand involvement. According to a press rele
- Novartis Launches Head-to-Head Trial of Remibrutinib vs Dupilumabhttps://practicaldermatology.com/news/novartis-launches-head-to-head-trial-of-remibrutinib-vs-dupilumab/2484430/Novartis, manufacturers of remibrutinib (Rhapsido), announced the launch of a US-based phase 3b clinical trial for the evaluation of early efficacy and safety of oral remibrutinib compared to injectable dupilumab in adults with chronic spontaneous urticaria (CSU) in
- Report: Antibiotics Linked to Shorter Biologic Persistence in Psoriasishttps://practicaldermatology.com/news/report-antibiotics-linked-to-shorter-biologic-persistence-in-psoriasis/2484451/Antibiotic exposure is associated with reduced persistence of biologic therapies in patients with psoriasis, according to findings from a nationwide French cohort study published in JAMA Dermatology.
- Remibrutinib Outperforms Placebo in Chronic Spontaneous Urticaria Control: Studyhttps://practicaldermatology.com/news/remibrutinib-outperforms-placebo-in-chronic-spontaneous-urticaria-control-study/2484429/Remibrutinib showed rapid and sustained efficacy in adults with chronic spontaneous urticaria (CSU) in a pooled analysis of the phase 3 REMIX-1 and REMIX-2 studies. The multicenter, double-blind, placebo-controlled trials looke
- Large Study Shows No Link Found Between Pemphigus and Psychiatric Disordershttps://practicaldermatology.com/news/large-study-shows-no-link-found-between-pemphigus-and-psychiatric-disorders/2484421/Results from a large retrospective cohort study analyzing more than 120 million U.S. electronic health records found no increased risk of psychiatric disorders in patients with pemphigus. "While 10–15% of dermatology patients ar
- FDA Clears Ultherapy PRIME for Skin Laxity on Arms, Abdomenhttps://practicaldermatology.com/news/fda-clears-ultherapy-prime-for-skin-laxity-on-arms-abdomen/2484325/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME for the treatment of skin laxity on the anterior arms, posterior arms, and abdomen, according to Merz Aesthetics. The device is now FDA-cleared for noninvasive lifting and firming of the face, neck, décolleté, and body.
- Analysis: Fibrotic Skin Diseases Linked to Elevated ASCVD Riskhttps://practicaldermatology.com/news/analysis-fibrotic-skin-diseases-linked-to-elevated-ascvd-risk/2484276/Patients with fibrotic skin diseases may have an elevated risk of atherosclerotic cardiovascular disease (ASCVD), according to new real-world data from the TriNetX platform. The study researchers conducted a retrospective cohort
- Sarecycline Monotherapy Delivers in Real-World Acne Studyhttps://practicaldermatology.com/news/sarecycline-monotherapy-delivers-in-real-world-acne-study/2484121/A post hoc analysis of the PROSES study found that oral sarecycline monotherapy is as effective as combination therapy with topicals in treating moderate-to-severe acne vulgaris (AV), based on 12-week outcomes from a real-world U.S. cohort presented by Dr. Hilary B